Evidence that has been or should be considered fur guidelines on antihypertensive treatment

G. Mancia, G. Grassi

Research output: Contribution to journalArticle

Abstract

Guidelines on antihypertensive drug treatment were first issued in the '70s by the American Joint National Committee and by the World Health Organization/International Society of Hypertension (WHO/ISH). They are updated periodically to allow for the effective treatment of high blood pressure. This paper will examine the importance of the results of clinical trials of antihypertensive treatment on hypertension guidelines. It will also examine the reasons why case-control and cohort studies should be interpreted with caution when guidelines are issued. Finally, the importance of surrogate endpoints for morbid and fatal events - such as the regression of left ventricular hypertrophy or early signs of renal damage - will be highlighted.

Original languageEnglish
Pages (from-to)8-12
Number of pages5
JournalInternational Journal of Clinical Practice, Supplement
Issue number92
Publication statusPublished - 1997

Fingerprint

Antihypertensive Agents
Guidelines
Hypertension
Left Ventricular Hypertrophy
Case-Control Studies
Cohort Studies
Biomarkers
Clinical Trials
Kidney

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{bee8c995269e432ba5dfcd76d436b0c8,
title = "Evidence that has been or should be considered fur guidelines on antihypertensive treatment",
abstract = "Guidelines on antihypertensive drug treatment were first issued in the '70s by the American Joint National Committee and by the World Health Organization/International Society of Hypertension (WHO/ISH). They are updated periodically to allow for the effective treatment of high blood pressure. This paper will examine the importance of the results of clinical trials of antihypertensive treatment on hypertension guidelines. It will also examine the reasons why case-control and cohort studies should be interpreted with caution when guidelines are issued. Finally, the importance of surrogate endpoints for morbid and fatal events - such as the regression of left ventricular hypertrophy or early signs of renal damage - will be highlighted.",
author = "G. Mancia and G. Grassi",
year = "1997",
language = "English",
pages = "8--12",
journal = "British journal of clinical practice. Supplement",
issn = "1368-504X",
publisher = "Medicom International, Inc.",
number = "92",

}

TY - JOUR

T1 - Evidence that has been or should be considered fur guidelines on antihypertensive treatment

AU - Mancia, G.

AU - Grassi, G.

PY - 1997

Y1 - 1997

N2 - Guidelines on antihypertensive drug treatment were first issued in the '70s by the American Joint National Committee and by the World Health Organization/International Society of Hypertension (WHO/ISH). They are updated periodically to allow for the effective treatment of high blood pressure. This paper will examine the importance of the results of clinical trials of antihypertensive treatment on hypertension guidelines. It will also examine the reasons why case-control and cohort studies should be interpreted with caution when guidelines are issued. Finally, the importance of surrogate endpoints for morbid and fatal events - such as the regression of left ventricular hypertrophy or early signs of renal damage - will be highlighted.

AB - Guidelines on antihypertensive drug treatment were first issued in the '70s by the American Joint National Committee and by the World Health Organization/International Society of Hypertension (WHO/ISH). They are updated periodically to allow for the effective treatment of high blood pressure. This paper will examine the importance of the results of clinical trials of antihypertensive treatment on hypertension guidelines. It will also examine the reasons why case-control and cohort studies should be interpreted with caution when guidelines are issued. Finally, the importance of surrogate endpoints for morbid and fatal events - such as the regression of left ventricular hypertrophy or early signs of renal damage - will be highlighted.

UR - http://www.scopus.com/inward/record.url?scp=0031390881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031390881&partnerID=8YFLogxK

M3 - Article

SP - 8

EP - 12

JO - British journal of clinical practice. Supplement

JF - British journal of clinical practice. Supplement

SN - 1368-504X

IS - 92

ER -